Bispecific antibodies that simultaneously target PD1 and other inhibitory receptors like TIGIT, TIM3, or LAG3 are designed to reinvigorate these exhausted T cells, potentially restoring their anti-tumor functionality. Here, LAG3 is linked to neoplasm.